At FDA/OC, I directed three concurrent biological research programs valued at up to $2M, coordinating protocol development and multisite execution. I also refined flow cytometry, qPCR, and western blot assays, increasing reproducibility by 25% and flow cytometry sensitivity by 20%.
At Johnson & Johnson, I coordinated oncology research across three development sites and integrated automation into cell characterization workflows, advancing three therapeutic candidates into downstream development. Across my work in oncology, gene therapy, vaccine development, and clinical research, I’ve supported scientific programs through analytical testing, regulatory-aligned operations, and clear program reporting.

